EBQ:TMP-SMX vs Placebo for Uncomplicated Skin Abscess

Revision as of 17:58, 17 April 2016 by Ostermayer (talk | contribs) (Created page with "{{JC info | title= Trimethoprim–Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess | abbreviation= Bactrim for Skin Abscesses | expansion= | published= March 3,...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
incomplete Journal Club Article
Talan DA et al.. "Trimethoprim–Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess". NEJM. 2016. 374(9):823-832.
PubMed Full text

Clinical Question

In settings with MRSA, does trimethoprim–sulfamethoxazole treatment after Incision and drainage of an abscess result in a greater cure rate?

Conclusion

Trimethoprim–sulfamethoxazole treatment resulted in a higher cure rate among patients with a drained cutaneous abscess than placebo for abscess that are successfully drained.

Major Points

Study Design

Population

Patient Demographics

Inclusion Criteria

Exclusion Criteria

Interventions

Outcomes

Primary Outcome

Secondary Outcomes

Subgroup analysis

Criticisms & Further Discussion

External Links

See Also

Funding

References

Retrieved from "https://www.wikem.org/w/index.php?title=EBQ:TMP-SMX_vs_Placebo_for_Uncomplicated_Skin_Abscess&oldid=64890"